Tianeptine
- Generic Name
- Tianeptine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O4S
- CAS Number
- 72797-41-2
- Unique Ingredient Identifier
- 0T493YFU8O
- Background
Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants .
...
- Indication
Used primarily in the treatment of major depressive disorder and anxiety . It is currently being studied for fibromyalgia pain treatment .
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- -
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Target Recruit Count
- 140
- Registration Number
- NCT06012552
- Locations
- 🇵🇱
Anna Klimkiewicz, Warsaw, Poland
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- National Cancer Institute, Egypt
- Target Recruit Count
- 90
- Registration Number
- NCT05935059
- Locations
- 🇪🇬
National Cancer Institute Cairo University, Cairo, Egypt
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Tianeptine for Treatment Resistant Depression
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04249596
- Locations
- 🇺🇸
Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Stanford Depression Research Clinic at Stanford University School of Medicine, Stanford, California, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
Brain Response to Serotonergic Medications in ASD
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- King's College London
- Target Recruit Count
- 100
- Registration Number
- NCT04145076
- Locations
- 🇬🇧
King's College London, London, United Kingdom
Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 164
- Registration Number
- NCT01309776
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Inje University Paik Hospital, Goyang, Korea, Republic of
Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 13
- Registration Number
- NCT00879372
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.